Current stock page

Catalysts

GKOS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - DevicesScore data as of Nov 18, 2026

GKOSGlaukos Corporation

Healthcare / Medical - Devices

Leader

Strong Relative Position

BullishEdge 8/10
$233.08−$10.17 (−4.18%)

Latest quote

  • Momentum
    90
  • Value
    30
  • Quality
    64
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 16, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 65/100

Momentum 90/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 18, 2026 · Sentiment 25.53%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 90/100AIQ Edge 8/10 Strong Relative Position
Beat rate
75%
6 of 8 reported periods
Average surprise
+88.8%
Across covered historical reports
Latest result
+587.8%
Oct 28, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 28, 2026—-$0.10$0.47+587.8%$168.04M$211.03M
Jul 29, 2026—-$0.21-$0.14+33.5%$150.93M$185.61M
Apr 29, 2026—-$0.30-$0.18+40.0%$137M$150.57M
Feb 17, 2026—-$0.22-$0.28-27.3%$136.4M$143.12M
Oct 29, 2025—-$0.27-$0.16+40.7%$129.46M$133.54M
Jul 30, 2025—-$0.26-$0.24+7.7%$122.43M$124.12M
Apr 30, 2025—-$0.33-$0.22+33.3%$102.78M$106.66M
Feb 20, 2025—-$0.38-$0.40-5.3%$100.96M$105.5M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
12
Buy
1
Hold
12-month analyst target
$234.00
+0.39% versus current price
Based on 13 analyst observations. Targets are estimates, not predictions.
Low target
$205.00
-12.05% vs latest price
Average target
$234.00
+0.39% vs latest price
High target
$255.00
+9.40% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 16, 2027

Next known earnings or reporting date.

EPS estimate$0.50

Current analyst expectation for the upcoming report.

Revenue estimate$233.33M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score90

Where event reaction would show up first.

AIQ score65/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
13
Average target
$234.00
Target upside
0.39%
Target range
$205.00 - $255.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
1
insidermonkey.com · Nov 12, 2026

What Supports Glaukos Corporation (GKOS) for a Powerful Profit Cycle?

Artisan Partners, an investment management company, released its third-quarter 2026 investor letter for the “Artisan U.S. Small-Cap Growth Strategy”. The letter can be downloaded here.

seekingalpha.com · Oct 29, 2026

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M (NYSE:GKOS)

Glaukos Q3 2026 earnings: record sales, raised 2026 guidance, and a $1B 2027 target as Epioxa and iDose TR gain traction.

seekingalpha.com · Oct 29, 2026

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDTCompany ParticipantsChristopher Lewis - Vice President of Investor Relations...

seekingalpha.com · Oct 11, 2026

Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS)

Glaukos has the iDose TR, which moves it beyond surgical devices into sustained drug delivery. Read why I lean neutral on GKOS shares right now.

seekingalpha.com · Oct 10, 2026

Glaukos Stock: The Second J-Code Rewrites The Risk Math (NYSE:GKOS)

Glaukos (GKOS) Q2 sales +50% as iDose TR & Epioxa drive 85% gross margin; 2026 guide raised. Read here for a detailed investment analysis.

Open full news and sentiment

GKOS Catalysts FAQ

What are the next catalysts for GKOS stock?

GKOS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move GKOS stock?

Upcoming events that could move GKOS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could GKOS's next earnings report affect the stock?

GKOS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive GKOS stock higher?

GKOS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt GKOS stock?

GKOS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.